- Trials with a EudraCT protocol (195)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
195 result(s) found for: Respiratory drive.
Displaying page 1 of 10.
EudraCT Number: 2018-000748-24 | Sponsor Protocol Number: -- | Start Date*: 2018-08-09 |
Sponsor Name:VUmc | ||
Full Title: Partial neuromuscular blockade to facilitate lung and diaphragm protective mechanical ventilation in ICU patients. A randomized controlled pilot study. | ||
Medical condition: Some patients develop high respiratory drive during partially supported mechanical ventilation which is associated with lung and diaphragm injury and worse clinical outcome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002567-57 | Sponsor Protocol Number: 1.0 | Start Date*: 2020-11-23 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: To determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in Covid-19 and augment effectiveness of supplementary oxygen therapy and respiratory support | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002287-16 | Sponsor Protocol Number: GS-US-218-1797 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) AT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005062-21 | Sponsor Protocol Number: MK1654-002 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK 1654 in Pre-Term and Full-Term Infants | |||||||||||||
Medical condition: Lower respiratory tract infections (LRI) caused by respiratory syncytial virus (RSV) A and B strains | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002208-37 | Sponsor Protocol Number: HVH237CIMM-COVID19 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Respiratory Research Unit 237, Hvidovre Hospital | |||||||||||||
Full Title: The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare util... | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002405-26 | Sponsor Protocol Number: MK-1654-004 | Start Date*: 2021-01-14 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | ||||||||||||||||||
Full Title: A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | ||||||||||||||||||
Medical condition: Prevention of RSV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA FI (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000472-28 | Sponsor Protocol Number: MK-7264-013 | Start Date*: 2018-06-01 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2a, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of MK-7264 on Acute Cough in Participants with Induced Viral Upper Respiratory Tract Infe... | |||||||||||||
Medical condition: Acute cough in participants with induced viral upper respiratory tract infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003181-12 | Sponsor Protocol Number: HOTPOT1 | Start Date*: 2016-10-07 |
Sponsor Name:Royal College of Surgeons in Ireland | ||
Full Title: Can sonographic assessment of pulmonary vascular reactivity following maternal hyperoxygenation therapy predict neonatal outcome in fetuses at risk of pulmonary hypertension? | ||
Medical condition: Persistent pulmonary hypertension of the newborn (PPHN) is a relatively common condition occurring in 7/1000 births and can result in significant cardiovascular instability in the newborn. It occur... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000267-17 | Sponsor Protocol Number: VPI-103-01 | Start Date*: 2007-02-21 | |||||||||||
Sponsor Name:Verus Pharmaceuticals Inc | |||||||||||||
Full Title: A SINGLE CENTRE, GAMMA SCINTIGRAPHY STUDY IN ASTHMATIC PATIENTS TO COMPARE PULMONARY DEPOSITION AND PHARMACOKINETICS OF ALBUTEROL INHALATION SOLUTION (AIS) DELIVERED VIA eFLOW NEBULISER AND SALBUTA... | |||||||||||||
Medical condition: The medical condition which is under investigation is Asthma. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001889-10 | Sponsor Protocol Number: STOIC | Start Date*: 2020-06-02 |
Sponsor Name:University of Oxford, Clinical Trials and Research Governance | ||
Full Title: Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation | ||
Medical condition: COVID 19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2016-001876-31 | Sponsor Protocol Number: SWAP | Start Date*: 2016-10-26 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Feasibility of the safe withdrawal of inhaled corticosteroids in patients with mild to moderate COPD prescribed outside guidelines (SWAP) | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001401-25 | Sponsor Protocol Number: QHD00012 | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older | |||||||||||||
Medical condition: Prevention of influenza infection in adults from 65 years of age and older | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002259-39 | Sponsor Protocol Number: TL-895-202 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Telios Pharma, Inc. | |||||||||||||
Full Title: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer | |||||||||||||
Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients with cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002848-22 | Sponsor Protocol Number: MV-004 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:Meissa Vaccines Inc. | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challe... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002696-18 | Sponsor Protocol Number: SUN101-303 | Start Date*: 2013-12-18 | |||||||||||
Sponsor Name:Sunovion Respiratory Development Inc. | |||||||||||||
Full Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-5 (Glycopyrrolate for Obstructive ... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001877-34 | Sponsor Protocol Number: HOT-Treated | Start Date*: 2016-11-25 | |||||||||||||||||||||
Sponsor Name:South London and Maudsley NHS Foundation Trust [...] | |||||||||||||||||||||||
Full Title: Improving understanding of Heroin Overdose Testing: diamorphine dose-escalation testing in a treated population | |||||||||||||||||||||||
Medical condition: Opioid Overdose | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004735-68 | Sponsor Protocol Number: AOUC-001-2013 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Azienda Ospedaliero Universitaria Careggi, Firenze | |||||||||||||
Full Title: Short-Term Effect of Levodropropizine on Respiratory Centre Output in Normal Subjects and Patients with Intractable Chronic Cough | |||||||||||||
Medical condition: Patients with chronic cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002749-42 | Sponsor Protocol Number: GS-US-205-1850 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution... | |||||||||||||
Medical condition: Cystic fibrosis and new onset lower respiratory tract culture positive for Pseudomonas aeruginosa | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) FR (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed) GR (Completed) DK (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004370-34 | Sponsor Protocol Number: POM-003 | Start Date*: 2018-04-09 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy | |||||||||||||
Medical condition: Late-onset Pompe disease (LOPD) in subjects receiving standard-of-care enzyme replacement therapy (ERT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004154-22 | Sponsor Protocol Number: TR701-132 | Start Date*: 2014-04-17 | |||||||||||
Sponsor Name:Trius Therapeutics, a Wholly Owned Subsidiary of Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Double-blind Study Comparing TR 701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia | |||||||||||||
Medical condition: Ventilated Gram-positive nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) GR (Completed) SK (Completed) CZ (Completed) EE (Completed) GB (Completed) HR (Completed) PT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
